Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity

被引：361

作者：

Kciuk, Mateusz ^{[1
,2
]}

Gielecinska, Adrianna ^{[1
,2
]}

Mujwar, Somdutt ^{[3
]}

Kolat, Damian ^{[4
]}

Kaluzinska-Kolat, Zaneta ^{[4
]}

Celik, Ismail ^{[5
]}

Kontek, Renata ^{[1
]}

机构：

[1] Univ Lodz, Dept Mol Biotechnol & Genet, PL-90237 Lodz, Poland

[2] Univ Lodz, Doctoral Sch Exact & Nat Sci, PL-90237 Lodz, Poland

[3] Chitkara Univ, Chitkara Coll Pharm, Rajpura 140401, Punjab, India

[4] Med Univ Lodz, Fac Med, Dept Expt Surg, PL-90136 Lodz, Poland

[5] Erciyes Univ, Fac Pharm, Dept Pharmaceut Chem, TR-38039 Kayseri, Turkiye

来源：

CELLS | 2023年 / 12卷 / 04期

关键词：

adriamycin; apoptosis; DNA damage response (DDR); doxorubicin; immunotherapy; PEGYLATED-LIPOSOMAL DOXORUBICIN; CELL-CYCLE ARREST; STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; OXYGEN SPECIES ROS; LIGAND; EXPRESSION; UP-REGULATION; OXIDATIVE STRESS; DRUG-DELIVERY; MRN COMPLEX;

D O I：

10.3390/cells12040659

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX's action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.

引用

页数：30

共 279 条

[41] Divergence to apoptosis from ROS induced cell cycle arrest: Effect of cadmium [J].

Chatterjee, Soumya ;

Kundu, Subhadip ;

Sengupta, Suman ;

Bhattacharyya, Arindam .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2009, 663 (1-2) :22-31

[42] DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion [J].

Chen, Baiwen ;

Hu, Jiajia ;

Hu, Xianting ;

Chen, Huifang ;

Bao, Rujuan ;

Zhou, Yatao ;

Ye, Youqiong ;

Zhan, Meixiao ;

Cai, Wei ;

Li, Huabin ;

Li, Hua-Bing .

NATURE COMMUNICATIONS, 2022, 13 (01)

[43] Pegylated liposomal doxorubicin (PLD)-containing regimen as a novel treatment of monomorphic epithelial intestinal T-cell lymphoma (MEITL): A case report and review of literature [J].

Chen, Yue ;

Xu, Hongzhi ;

Shan, Ningning ;

Qu, Huiting .

MEDICINE, 2022, 101 (44) :E31326

[44] Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv [J].

Cheng, Wilson W. K. ;

Allen, Theresa M. .

JOURNAL OF CONTROLLED RELEASE, 2008, 126 (01) :50-58

[45] Regulated cell death pathways in doxorubicin-induced cardiotoxicity [J].

Christidi, Effimia ;

Brunham, Liam R. .

CELL DEATH & DISEASE, 2021, 12 (04)

[46] Metronomic oral doxorubicin in combination of Chkl inhibitor MK-8776 for p53-deficient breast cancer treatment [J].

Chung, Seung Woo ;

Kim, Gui Chul ;

Kweon, Seho ;

Lee, Hanul ;

Choi, Jeong Uk ;

Mahmud, Foyez ;

Chang, Hyo Won ;

Kim, Ji Won ;

Son, Woo-Chan ;

Kim, Sang Yoon ;

Byun, Youngro .

BIOMATERIALS, 2018, 182 :35-43

[47] ATR: an essential regulator of genome integrity [J].

Cimprich, Karlene A. ;

Cortez, David .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2008, 9 (08) :616-627

[48] Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines [J].

Coimbra, Maria ;

Crielaard, Bart J. ;

Storm, Gert ;

Schiffelers, Raymond M. .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :232-238

[49] Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations [J].

Coldwell, Kate E. ;

Cutts, Suzanne M. ;

Ognibene, Ted J. ;

Henderson, Paul T. ;

Phillips, Don R. .

NUCLEIC ACIDS RESEARCH, 2008, 36 (16)

[50]

Cui JC, 2022, AM J CANCER RES, V12, P1577

← 1 2 3 4 5 6 7 8 9 10 →